bismuth has been researched along with pentetic acid in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atcher, RW; Rotmensch, J; Schwartz, JL; Shadley, JD; Tang, J; Whitlock, JL | 2 |
| Foster, RR; Overman, RF | 1 |
| Apostolidis, C; Bos, E; Doornmalen, AV; Geerlings, MW; Kaspersen, FM; Molinet, R | 1 |
| Atcher, RW; Hines, JJ; Humm, JL; Macklis, RM; Palayoor, ST | 1 |
| Bauer, M; Krause, W; Muschick, P; Press, WR; Schuhmann-Giampieri, G | 1 |
| Brechbiel, M; Kennel, SJ; Mirzadeh, S; Stabin, M; Yoriyaz, H | 1 |
| Abbas Rizvi, SM; Allen, BJ; Goozee, G; Sarkar, S | 1 |
| Brechbiel, MW; Colcher, D; Gansow, OA; Milenic, DE; Mirzadeh, S; Pippin, CG; Roselli, M; Schlom, J | 1 |
| Brechbiel, MW; Carrasquillo, JA; Garmestani, K; Park, CW; Pastan, I; Wong, K; Yao, Z; Zhang, M | 1 |
| Brechbiel, MW | 1 |
| Allen, BJ; Andronicos, NM; Ranson, M; Rizvi, S; Tian, Z | 1 |
| Bethge, WA; Brechbiel, MW; Fisher, DR; Hamlin, DK; Sandmaier, BM; Santos, EB; Storb, R; Wilbur, DS | 1 |
| Allen, BJ; Brechbiel, M; Li, Y; Morgenstern, A; Perkins, AC; Qu, CF; Rizvi, SM; Smith, R; Songl, YJ | 1 |
| Abbas Rizvi, SM; Allen, BJ; Apostolidis, C; Li, Y; Morgenstern, A; Qu, CF; Raja, C; Song, EY | 1 |
| Brechbiel, MW; Kelly, MP; Lee, FT; Scott, AM; Smyth, FE; Tahtis, K | 1 |
| Abbas Rizvi, SM; Abbas, K; Allen, BJ; Apostolidis, C; Beretov, J; Kearsley, JH; Morgenstern, A; Raja, C; Russell, PJ; Song, EY | 1 |
| Alke, A; Blechert, B; Bruchertseifer, F; Drecoll, E; Essler, M; Gaertner, FC; Miederer, M; Morgenstern, A; Müller, JM; Seidl, C; Senekowitsch-Schmidtke, R; Vallon, M | 1 |
| Fonseca, IT; Jorge, EO; Neto, MM; Rocha, MM | 1 |
| Bruchertseifer, F; Lingappa, M; Morgenstern, A; Sgouros, G; Song, H; Thompson, S | 1 |
| Blechert, B; Bruchertseifer, F; Essler, M; Gärtner, FC; Morgenstern, A; Neff, F; Seidl, C; Senekowitsch-Schmidtke, R | 1 |
| Champion, J; Le Du, A; Montavon, G; Morgenstern, A; Rabung, T | 1 |
| Cheng, Z; Huang, SW; Li, H; Li, YS; Liao, RF; Liu, HG; Lu, ST; Lucie Zafitatsimo, BV; Wu, B; Xu, HB; Yu, H; Zhang, Y; Zhu, XL | 1 |
| Hai Phong, N; Nhi Phuong, N; Quoc Hung, L; Thai Long, H; Thị Hue, N; Uyen, TH; Van Hop, N | 1 |
| Chen, MY; Dang, YY; Fu, JJ; Guo, JJ; Huang, YG; Lei, XP; Li, JX; Li, SP; Lin, YL; Lin, ZX; Liu, JP; Qin, AP; Wu, D; Yu, XY; Zhang, LY; Zhang, Q; Zhang, Y; Zhao, XY | 1 |
1 review(s) available for bismuth and pentetic acid
| Article | Year |
|---|---|
Chelated metal ions for therapeutic and diagnostic applications.
Topics: Animals; Antibodies, Monoclonal; Bismuth; Chelating Agents; Humans; Isotope Labeling; Isotopes; Metals; Neoplasms; Pentetic Acid | 2001 |
24 other study(ies) available for bismuth and pentetic acid
| Article | Year |
|---|---|
The effects of radon daughter alpha-particle irradiation in K1 and xrs-5 CHO cell lines.
Topics: Alpha Particles; Animals; Bismuth; Cell Line; Cell Survival; Chromosome Aberrations; Chromosome Deletion; Cricetinae; DNA; DNA Mutational Analysis; Dose-Response Relationship, Radiation; Drug Resistance; In Vitro Techniques; Pentetic Acid; Radioisotopes; Radon; Regression Analysis; Thioguanine; X-Rays | 1991 |
Comparison of radon-daughter-induced effects in repair-proficient and repair-deficient CHO cell lines.
Topics: Animals; Bismuth; Cell Line; Chromosome Aberrations; Chromosomes; Cricetinae; Cricetulus; DNA Repair; Hypoxanthine Phosphoribosyltransferase; Mutagens; Mutation; Pentetic Acid; Radioisotopes; Radon; Thioguanine; X-Rays | 1990 |
Analysis of DTPA in urine.
Topics: Bismuth; Coloring Agents; Methods; Pentetic Acid | 1972 |
Cytotoxicity of 213Bi- and 225Ac-immunoconjugates.
Topics: Actinium; Animals; Antibody Specificity; Bismuth; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Dose-Response Relationship, Radiation; Humans; Immunoconjugates; Immunoglobulin G; Kinetics; Mice; Pentetic Acid; Radioisotopes; Tumor Cells, Cultured | 1995 |
G2M arrest and apoptosis in murine T lymphoma cells following exposure to 212Bi alpha particle irradiation.
Topics: Alpha Particles; Animals; Apoptosis; Bismuth; Cell Cycle; Cell Division; Cell Line; Flow Cytometry; G2 Phase; Lymphoma, T-Cell; Mice; Microscopy, Electron; Pentetic Acid; Radioisotopes | 1993 |
Ytterbium- and dysprosium-EOB-DTPA. A new prototype of liver-specific contrast agents for computed tomography.
Topics: Animals; Biological Products; Bismuth; Bone and Bones; Cerium; Chelating Agents; Chemical Phenomena; Chemistry, Physical; Contrast Media; Dysprosium; Erythrocytes; Humans; Lanthanum; Lead; Liver; Lutetium; Minerals; Organometallic Compounds; Osmolar Concentration; Partial Thromboplastin Time; Pentetic Acid; Phantoms, Imaging; Praseodymium; Protein Binding; Rabbits; Radiographic Image Enhancement; Rats; Tissue Distribution; Tomography, X-Ray Computed; Viscosity; Ytterbium | 1996 |
Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the alpha-particle emitter 213Bi.
Topics: Animals; Antibodies, Monoclonal; Bismuth; Dose-Response Relationship, Radiation; Female; Isothiocyanates; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Pentetic Acid; Radioisotopes; Radiopharmaceuticals; Yttrium Radioisotopes | 1999 |
Radioimmunoconjugates for targeted alpha therapy of malignant melanoma.
Topics: Antibodies, Monoclonal; Bismuth; Chelating Agents; DNA, Neoplasm; Humans; Immunoconjugates; Isothiocyanates; Melanoma; Nucleic Acid Synthesis Inhibitors; Pentetic Acid; Radioisotopes; Terbium; Thymidine; Time Factors; Tumor Cells, Cultured | 2000 |
In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Bismuth; Chelating Agents; Female; Immunoconjugates; Kidney; Mice; Mice, Nude; Pentetic Acid; Radioimmunoassay; Radioimmunotherapy; Radioisotopes; Spleen; Tissue Distribution | 2001 |
Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides.
Topics: Animals; Bismuth; Cell Line; Chelating Agents; Female; Immunoconjugates; Indicators and Reagents; Isothiocyanates; Mice; Mice, Nude; Pentetic Acid; Radiopharmaceuticals; Rats; Tissue Distribution; Tumor Cells, Cultured | 2001 |
In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells.
Topics: Bismuth; Breast Neoplasms; Cell Survival; Female; Humans; Kinetics; Neoplasm Metastasis; Pentetic Acid; Plasminogen Activator Inhibitor 2; Radioisotopes; Recombinant Proteins; Tumor Cells, Cultured | 2002 |
Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.
Topics: Animals; Bismuth; Bone Marrow Transplantation; Dogs; Dose-Response Relationship, Radiation; Graft Survival; Immunoconjugates; Immunosuppressive Agents; Leukocyte Common Antigens; Models, Animal; Pentetic Acid; Radioisotopes; Tissue Distribution; Transplantation Conditioning; Transplantation, Homologous | 2002 |
In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Bismuth; Cell Line, Tumor; Humans; Isothiocyanates; Mice; Mucin-1; Mucins; Pancreatic Neoplasms; Pentetic Acid; Radioimmunotherapy; Xenograft Model Antitumor Assays | 2005 |
Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model.
Topics: Animals; Bismuth; Chelating Agents; Cycloheximide; Humans; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pentetic Acid; Plasminogen Activator Inhibitor 2; Prostatic Neoplasms; Rabbits; Radioisotopes; Serine Proteinase Inhibitors | 2006 |
Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Bismuth; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Immunoglobulin Fab Fragments; Isothiocyanates; Lewis Blood Group Antigens; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Survival Rate; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |
Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Bismuth; Cell Line, Tumor; Chelating Agents; Clinical Trials as Topic; Humans; Immunoconjugates; Pentetic Acid; Quality Control; Radioisotopes; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.
Topics: Animals; Antineoplastic Agents; Bismuth; Cell Line, Tumor; Cell Nucleus; Drug Delivery Systems; Endocytosis; Humans; Isotope Labeling; Mice; Pentetic Acid; Peptides; Peritoneal Neoplasms; Radioisotopes; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Studies on the stripping voltammetric determination and speciation of chromium at a rotating-disc bismuth film electrode.
Topics: Adsorption; Bismuth; Chromium; Electrochemistry; Electrodes; Green Chemistry Technology; Nitrates; Pentetic Acid; Rotation; Time Factors; Water | 2010 |
Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
Topics: Alpha Particles; Animals; Bismuth; Female; Immunoconjugates; Isothiocyanates; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Metastasis; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Rats; Receptor, ErbB-2 | 2010 |
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Topics: Actinium; Animals; Bismuth; Cell Line, Tumor; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Kidney; Mice; Organometallic Compounds; Pentetic Acid; Peptides; Peritoneal Neoplasms; Radioisotopes; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
DTPA complexation of bismuth in human blood serum.
Topics: Animals; Bismuth; Cattle; Chelating Agents; Edetic Acid; gamma-Globulins; Humans; In Vitro Techniques; Isothiocyanates; Pentetic Acid | 2012 |
Gadolinium-chelate functionalized bismuth nanotheranostic agent for in vivo MRI/CT/PAI imaging-guided photothermal cancer therapy.
Topics: Animals; Bismuth; Contrast Media; Female; Gadolinium; Hemolysis; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Multimodal Imaging; Nanoparticles; Pentetic Acid; Photoacoustic Techniques; Phototherapy | 2018 |
Determination of Chromium in Natural Water by Adsorptive Stripping Voltammetry Using
Topics: Adsorption; Bismuth; Catalysis; Chromium; Electrochemistry; Electrodes; Limit of Detection; Nitrates; Pentetic Acid; Water Pollutants | 2020 |
Bismuth chelate as a contrast agent for X-ray computed tomography.
Topics: Animals; Bismuth; Contrast Media; Iohexol; Kidney; Metal Nanoparticles; Mice; Pentetic Acid; Tissue Distribution; Tomography, X-Ray Computed; Whole Body Imaging | 2020 |